Inhibition of striatal dopamine release by glycine and glycyldodecylamide

Brain Research Bulletin

Volumn 52, Issue 3, 2000, Pages 213-216

  Javitt, Daniel C ^a,b   Sershen, Henry ^a   Hashim, Audrey ^a   Lajtha, Abel ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mouse; NMDA receptors; Phencyclidine; Schizophrenia

Indexed keywords

5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; GLYCINE; GLYCYLDODECYLAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINOQUINOLINES; ANIMALS; CORPUS STRIATUM; DOPAMINE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; MICE; N-METHYLASPARTATE; NEURONS; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SUBCELLULAR FRACTIONS; TRITIUM;

EID: 0034015991     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(00)00258-6     Document Type: Article

References (25)

1. Berger A.J., Dieudonne S., Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80:1998;3336-3340.
2. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA. 95:1998;15730-15734.
3. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects Application of a novel PET approach . Synapse. 29:1998;142-147.
4. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry. 3:1996;241-253.
5. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 56:1999;21-27.
6. Hanania T., Johnson K.M. Regulation of NMDA-stimulated [14C]GABA and [3H]acetylcholine release by striatal glutamate and dopamine receptors. Brain Res. 844:1999;106-117.
7. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 56:1999;29-36.
8. Javitt D.C., Balla A., Sershen H., Lajtha A. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry. 45:1999;668-679.
9. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake Implications for schizophrenia and substance abuse . Psychopharmacology. 129:1997;96-98.
10. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 17:1997;202-204.
11. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
12. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia . Neuropsychopharmacology. 20:1999;201-225.
13. Krebs M.O., Kemel M.L., Gauchy C., Desban M., Glowinski J. Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. Eur. J. Pharmacol. 166:1989;567-570.
14. Krebs M.O., Kemel M.L., Gauchy C., Desban M., Glowinski J. Local GABAergic regulation of the N-methyl-D-aspartate-evoked release of dopamine is more prominent in striosomes than in matrix of the rat striatum. Neuroscience. 57:1993;249-260.
15. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 93:1996;9235-9240.
16. Nankai M., Fage D., Carter C. Striatal NMDA receptor subtypes The pharmacology of N-methyl-D-aspartate-evoked dopamine, gamma-aminobutyric acid, acetylcholine and spermidine release . Eur. J. Pharmacol. 286:1995;61-70.
17. Nilsson M., Carlsson A., Carlsson M.L. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J. Neural. Transm. 104:1997;1195-1205.
18. Obrenovitch T.P., Hardy A.M., Urenjak J. High extracellular glycine does not potentiate N-methyl-D-aspartate-evoked depolarization in vivo. Brain Res. 746:1997;190-194.
19. Ransom R.W., Deschenes N.L. Glycine modulation of NMDA-evoked release of [3H] acetylcholine and [3H]dopamine from rat striatal slices. Neurosci. Lett. 96:1989;323-328.
20. Reader T.A., Dewar K.M. Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum Implications for human Parkinson's disease . Neurochem. Int. 34:1999;1-21.
21. Sakata K., Sato K., Schloss P., Betz H., Shimada S., Tohyama M. Characterization of glycine release mediated by glycine transporter 1 stably expressed in HEK-293 cells. Brain Res. Mol. Brain Res. 49:1997;89-94.
22. Smith K.E., Borden L.A., Hartig P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 8:1992;927-935.
23. Supplisson S., Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J. Neurosci. 17:1997;4580-4590.
24. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089.
25. Whitton P.S. Glutamatergic control over brain dopamine release in vivo and in vitro. Neurosci. Biobehav. Rev. 21:1997;481-488.